Sponsor: Aravive, Inc.
Sponsor Study ID: AVB500-RCC-003
Study Title: A Phase 1B/2 Study of AVBS6500 in Combination with Cabozantinib, AVB S6 500 in Combination with Cabozantimib and Nivolumab, and AVB S6 500 Monotherapy in Patient with Advanced or Metastatic Clear Cell Renal Cell Carcinoma
CTO #: 103438
NCT Number: NCT04300140
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Kidney
Study Objectives: This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone.